摘要
肝细胞癌是一种异质性疾病,其发生的复杂性与表观遗传修饰有关.哺乳动物蛋白质精氨酸甲基转移酶(protein arginine methyltransferases,PRMTs)可介导细胞的表观遗传修饰,并在肝细胞癌的发生、发展、治疗及预后中发挥重要作用.PRMTs催化组蛋白和非组蛋白靶蛋白的精氨酸残基发生单甲基化和(对称的及不对称的)二甲基化.PRMT1、2、3、4、5、6、7、9等家族成员在肝细胞癌中的作用不同,涉及癌细胞生长、转移、治疗和预后等.选择性和特异性PRMTs抑制剂的研究开发有望为临床肝细胞癌的治疗和预后提供新思路和新靶点.本文重点概述PRMTs在肝细胞癌中作用的机制研究进展.
Abstract
Hepatocellular carcinoma(HCC)is a heterogeneous disease,and the complexity of its occurrence is associated with epigenetic modifications.Mammalian protein arginine methyltrans-ferases(PRMTs)mediate epigenetic modifications of cells,and play an important role in the oc-currence,development,treatment,and prognosis of hepatocellular carcinoma.PRMTs catalyze the monomethylation and(symmetric and asymmetric)dimethylation of arginine residues in his-tones and non-histone targets.PRMT family members,such as PRMT1,2,3,4,5,6,7,and 9,play different roles in hepatocellular carcinoma,involving cancer cell growth,metastasis,treatment,prognosis,etc.The research and development of selective and specific PRMT inhibi-tors are expected to provide new ideas and targets for the clinical treatment and improvement of the prognosis of hepatocellular carcinoma.This review focuses on the research progress on the role of PRMTs in hepatocellular carcinoma.
基金项目
山西省基础研究计划项目(202203021221194)
山西省回国留学人员科研项目(2020-081)
NETL
NSTL
万方数据